PL1801209T3 - Zmodyfikowany genomowy RNA ludzkiego wirusa zapalenia wątroby typu C posiadający zdolność replikacji autonomicznej - Google Patents
Zmodyfikowany genomowy RNA ludzkiego wirusa zapalenia wątroby typu C posiadający zdolność replikacji autonomicznejInfo
- Publication number
- PL1801209T3 PL1801209T3 PL05781421T PL05781421T PL1801209T3 PL 1801209 T3 PL1801209 T3 PL 1801209T3 PL 05781421 T PL05781421 T PL 05781421T PL 05781421 T PL05781421 T PL 05781421T PL 1801209 T3 PL1801209 T3 PL 1801209T3
- Authority
- PL
- Poland
- Prior art keywords
- coding sequence
- protein coding
- genomic rna
- virus genomic
- hepatitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24241—Use of virus, viral particle or viral elements as a vector
- C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004243975 | 2004-08-24 | ||
JP2004290801 | 2004-10-01 | ||
JP2005069527 | 2005-03-11 | ||
JP2005069725 | 2005-03-11 | ||
PCT/JP2005/015833 WO2006022422A1 (ja) | 2004-08-24 | 2005-08-24 | 自律複製能を有する改変されたヒトc型肝炎ウイルスゲノムrna |
EP05781421A EP1801209B1 (en) | 2004-08-24 | 2005-08-24 | Modified human hepatitis c virus genomic rna having autonomous replicative competence |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1801209T3 true PL1801209T3 (pl) | 2011-07-29 |
Family
ID=35967617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL05781421T PL1801209T3 (pl) | 2004-08-24 | 2005-08-24 | Zmodyfikowany genomowy RNA ludzkiego wirusa zapalenia wątroby typu C posiadający zdolność replikacji autonomicznej |
Country Status (13)
Country | Link |
---|---|
US (2) | US8454973B2 (pl) |
EP (1) | EP1801209B1 (pl) |
JP (1) | JP4931591B2 (pl) |
KR (1) | KR101262773B1 (pl) |
CN (1) | CN101048502B (pl) |
AT (1) | ATE499442T1 (pl) |
AU (1) | AU2005275713B2 (pl) |
CA (1) | CA2578021C (pl) |
DE (1) | DE602005026545D1 (pl) |
HK (1) | HK1112481A1 (pl) |
PL (1) | PL1801209T3 (pl) |
PT (1) | PT1801209E (pl) |
WO (1) | WO2006022422A1 (pl) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006038129A2 (en) * | 2004-10-01 | 2006-04-13 | Novartis Vaccines And Diagnostics Srl | Hepatitis c virus replication system |
WO2006096459A2 (en) | 2005-03-04 | 2006-09-14 | The Rockefeller University | Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof |
US8364417B2 (en) * | 2007-02-15 | 2013-01-29 | 454 Life Sciences Corporation | System and method to correct out of phase errors in DNA sequencing data by use of a recursive algorithm |
CN101390101B (zh) | 2006-02-16 | 2012-05-23 | 454生命科学公司 | 用于校正核酸序列数据中的引物延伸误差的系统和方法 |
JP2008161080A (ja) * | 2006-12-27 | 2008-07-17 | Japan Health Science Foundation | C型肝炎ウイルス阻害剤を検出するためのアッセイ方法 |
US8945584B2 (en) | 2007-04-13 | 2015-02-03 | Hvidovre Hospital | Cell culture system of a hepatitis C genotype 3a and 2a chimera |
US8454974B2 (en) | 2007-04-13 | 2013-06-04 | Hvidovre Hospital | Adaptive mutations allow establishment of JFH1-based cell culture systems for hepatitis C virus genotype 4A |
CN101688197A (zh) * | 2007-04-27 | 2010-03-31 | 株式会社先端生命科学研究所 | Hcv基因 |
US8618275B2 (en) | 2007-05-18 | 2013-12-31 | Hvidovre Hospital | Efficient cell culture system for hepatitis C virus genotype 5A |
US20100278865A1 (en) * | 2007-07-13 | 2010-11-04 | Takaji Wakita | Production and use of epitope-tagged hepatitis c virus particle |
US20100291545A1 (en) * | 2007-07-25 | 2010-11-18 | Takaji Wakita | Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereof |
US8563706B2 (en) | 2007-12-20 | 2013-10-22 | Hvidovre Hospital | Efficient cell culture system for hepatitis C virus genotype 1A and 1B |
US8569472B2 (en) | 2007-12-20 | 2013-10-29 | Hvidovre Hospital | Efficient cell culture system for hepatitis C virus genotype 6A |
WO2009131203A1 (ja) | 2008-04-25 | 2009-10-29 | 東レ株式会社 | C型肝炎ウイルス由来のキメラ遺伝子を含む核酸 |
US8663653B2 (en) | 2008-08-15 | 2014-03-04 | Hvidovre Hospital | Efficient cell culture system for hepatitis C virus genotype 2B |
WO2010017819A1 (en) | 2008-08-15 | 2010-02-18 | Hvidovre Hospital | EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 7a |
CN102227445B (zh) | 2008-09-30 | 2014-12-17 | 东丽株式会社 | 结合丙型肝炎病毒的包膜蛋白2的抗体以及利用所述抗体鉴定丙型肝炎病毒的基因型的方法 |
US8772022B2 (en) | 2008-10-03 | 2014-07-08 | Hvidovre Hospital | Hepatitis C virus expressing reporter tagged NS5A protein |
JP5692738B2 (ja) * | 2009-07-28 | 2015-04-01 | 国立大学法人 鹿児島大学 | ウイルスの濃縮方法および磁性体組成物 |
US20120251572A1 (en) | 2009-09-30 | 2012-10-04 | Takaji Wakita | Hepatitis c virus vaccine composition |
US8592559B2 (en) | 2009-10-30 | 2013-11-26 | Toray Industries, Inc. | Antibody having activity of inhibiting hepatitis C virus (HCV) infection and use thereof |
WO2011156707A2 (en) | 2010-06-11 | 2011-12-15 | Life Technologies Corporation | Alternative nucleotide flows in sequencing-by-synthesis methods |
AU2011313158B2 (en) * | 2010-10-08 | 2014-09-25 | Advanced Life Science Institute, Inc. | Hepatitis C virus gene |
US8666678B2 (en) | 2010-10-27 | 2014-03-04 | Life Technologies Corporation | Predictive model for use in sequencing-by-synthesis |
US10273540B2 (en) | 2010-10-27 | 2019-04-30 | Life Technologies Corporation | Methods and apparatuses for estimating parameters in a predictive model for use in sequencing-by-synthesis |
EP2659408B1 (en) | 2010-12-29 | 2019-03-27 | Life Technologies Corporation | Time-warped background signal for sequencing-by-synthesis operations |
EP3582224A1 (en) | 2010-12-30 | 2019-12-18 | Life Technologies Corporation | Models for analyzing data from sequencing-by-synthesis operations |
WO2012092515A2 (en) | 2010-12-30 | 2012-07-05 | Life Technologies Corporation | Methods, systems, and computer readable media for nucleic acid sequencing |
US20130060482A1 (en) | 2010-12-30 | 2013-03-07 | Life Technologies Corporation | Methods, systems, and computer readable media for making base calls in nucleic acid sequencing |
EP2692861A4 (en) | 2011-03-31 | 2014-12-17 | Jp Nat Inst Infectious Disease | NUCLEIC ACID CONSTRUCTURE WITH NUCLEIC ACID DERIVED FROM GENOTYP-1B HCV GENOMINE, THEREFORE, WITH HCV GENOM REPLICATED CELLS, AND METHOD FOR THE PRODUCTION OF INFECTIOUS HCV PARTICLES |
EP3366782B1 (en) | 2011-04-08 | 2021-03-10 | Life Technologies Corporation | Phase-protecting reagent flow orderings for use in sequencing-by-synthesis |
CN103703133B (zh) | 2011-05-31 | 2016-03-09 | 日本国立感染症研究所 | 来自丙型肝炎病毒j6cf株基因组的突变体复制子 |
AU2012302666B2 (en) | 2011-08-31 | 2017-05-25 | Inserm Institut National De La Sante Et De La Recherche Medicale | Nucleic acid construct including nucleic acid derived from genotype 3a HCV genome |
US10704164B2 (en) | 2011-08-31 | 2020-07-07 | Life Technologies Corporation | Methods, systems, computer readable media, and kits for sample identification |
JP2015509000A (ja) * | 2012-01-13 | 2015-03-26 | ギリアド ファーマセット エルエルシー | Hcvポリメラーゼ複合体の結晶構造および使用方法 |
US9646132B2 (en) | 2012-05-11 | 2017-05-09 | Life Technologies Corporation | Models for analyzing data from sequencing-by-synthesis operations |
US10329608B2 (en) | 2012-10-10 | 2019-06-25 | Life Technologies Corporation | Methods, systems, and computer readable media for repeat sequencing |
US20140296080A1 (en) | 2013-03-14 | 2014-10-02 | Life Technologies Corporation | Methods, Systems, and Computer Readable Media for Evaluating Variant Likelihood |
US9926597B2 (en) | 2013-07-26 | 2018-03-27 | Life Technologies Corporation | Control nucleic acid sequences for use in sequencing-by-synthesis and methods for designing the same |
US10410739B2 (en) | 2013-10-04 | 2019-09-10 | Life Technologies Corporation | Methods and systems for modeling phasing effects in sequencing using termination chemistry |
WO2016060974A1 (en) | 2014-10-13 | 2016-04-21 | Life Technologies Corporation | Methods, systems, and computer-readable media for accelerated base calling |
WO2016183478A1 (en) | 2015-05-14 | 2016-11-17 | Life Technologies Corporation | Barcode sequences, and related systems and methods |
US10619205B2 (en) | 2016-05-06 | 2020-04-14 | Life Technologies Corporation | Combinatorial barcode sequences, and related systems and methods |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE423204T1 (de) * | 1996-11-08 | 2009-03-15 | Us Gov Health & Human Serv | Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln |
ATE362538T1 (de) * | 1999-06-04 | 2007-06-15 | Us Gov Health & Human Serv | Klonierte genome von infektiösen hepatitis c viren genotyp 2a und deren verwendungen |
PT1233782E (pt) * | 1999-12-01 | 2009-02-13 | Novartis Vaccines & Diagnostic | Estimulação da produção de anticorpos específicos para o hcv |
IL137522A (en) * | 2000-07-26 | 2007-06-17 | Drk Blutspendediendst Baden Wu | HCV human monoclonal antibody E2 glycoprotein antibody |
JP4880116B2 (ja) * | 2000-12-01 | 2012-02-22 | 財団法人 東京都医学総合研究所 | 劇症c型肝炎ウイルス株の遺伝子 |
US20050250093A1 (en) | 2002-04-03 | 2005-11-10 | Gates Adam T | Hepatitis c virus sub-genomic replicons |
CN1833024B (zh) * | 2003-05-26 | 2011-08-31 | 东丽株式会社 | 含有衍生自基因型2a丙肝病毒(HCV)基因组的核酸的核酸构建体和具有转移入其中的这样的核酸构建体的细胞 |
WO2006038129A2 (en) * | 2004-10-01 | 2006-04-13 | Novartis Vaccines And Diagnostics Srl | Hepatitis c virus replication system |
WO2006096459A2 (en) | 2005-03-04 | 2006-09-14 | The Rockefeller University | Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof |
WO2009131203A1 (ja) * | 2008-04-25 | 2009-10-29 | 東レ株式会社 | C型肝炎ウイルス由来のキメラ遺伝子を含む核酸 |
-
2005
- 2005-08-24 AU AU2005275713A patent/AU2005275713B2/en active Active
- 2005-08-24 US US11/660,794 patent/US8454973B2/en active Active
- 2005-08-24 JP JP2006532743A patent/JP4931591B2/ja active Active
- 2005-08-24 WO PCT/JP2005/015833 patent/WO2006022422A1/ja active Application Filing
- 2005-08-24 CA CA2578021A patent/CA2578021C/en active Active
- 2005-08-24 AT AT05781421T patent/ATE499442T1/de not_active IP Right Cessation
- 2005-08-24 EP EP05781421A patent/EP1801209B1/en active Active
- 2005-08-24 CN CN2005800364134A patent/CN101048502B/zh active Active
- 2005-08-24 PT PT05781421T patent/PT1801209E/pt unknown
- 2005-08-24 KR KR1020077006497A patent/KR101262773B1/ko active IP Right Grant
- 2005-08-24 PL PL05781421T patent/PL1801209T3/pl unknown
- 2005-08-24 DE DE602005026545T patent/DE602005026545D1/de active Active
-
2008
- 2008-01-30 HK HK08101157.9A patent/HK1112481A1/xx unknown
-
2013
- 2013-01-04 US US13/734,630 patent/US9175269B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2005275713B2 (en) | 2010-08-05 |
PT1801209E (pt) | 2011-05-26 |
HK1112481A1 (en) | 2008-09-05 |
CA2578021C (en) | 2014-11-18 |
AU2005275713A1 (en) | 2006-03-02 |
US20130115592A1 (en) | 2013-05-09 |
EP1801209A4 (en) | 2007-12-05 |
US20090176200A1 (en) | 2009-07-09 |
CA2578021A1 (en) | 2006-03-02 |
EP1801209A1 (en) | 2007-06-27 |
ATE499442T1 (de) | 2011-03-15 |
JP4931591B2 (ja) | 2012-05-16 |
WO2006022422A1 (ja) | 2006-03-02 |
KR101262773B1 (ko) | 2013-05-10 |
EP1801209B1 (en) | 2011-02-23 |
US8454973B2 (en) | 2013-06-04 |
CN101048502A (zh) | 2007-10-03 |
US9175269B2 (en) | 2015-11-03 |
JPWO2006022422A1 (ja) | 2008-05-08 |
CN101048502B (zh) | 2012-03-21 |
KR20070045333A (ko) | 2007-05-02 |
DE602005026545D1 (de) | 2011-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1112481A1 (en) | Modified human hepatitis c virus genomic rna having autonomous replicative competence | |
Mandl et al. | Spontaneous and engineered deletions in the 3′ noncoding region of tick-borne encephalitis virus: construction of highly attenuated mutants of a flavivirus | |
WO2009014216A1 (ja) | C型肝炎ウイルス(hcv)に対して感染阻害活性を有する抗体およびその用途 | |
Jones et al. | The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus | |
Fan et al. | The intrinsic disorder status of the human hepatitis C virus proteome | |
Ezelle et al. | Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector | |
WO2006096459A3 (en) | Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof | |
JP2008516610A5 (pl) | ||
EP1930416A4 (en) | NEW RECOMBINANT PARTICLE SIMILAR TO HUMAN HEPATITIS C VIRUS AND METHOD FOR THE MANUFACTURE THEREOF | |
HK1092498A1 (en) | Composition containing the polyprotein ns3/ns4 and the polypeptide ns5b of hcv, expression vectors comprising corresponding nucleic sequences and the therapeutic application thereof | |
Imhof et al. | Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6 | |
Londono-Renteria et al. | A brief review of West Nile virus biology | |
Tajima et al. | Restoration of replication-defective dengue type 1 virus bearing mutations in the N-terminal cytoplasmic portion of NS4A by additional mutations in NS4B | |
ATE555800T1 (de) | Zusammensetzung mit dem polyprotein ns3/ns4 und dem polypeptid ns5b von hcv, expressionsvektoren mit den entsprechenden nukleinsäuresequenzen und ihre therapeutische verwendung | |
Khasnatinov et al. | Tick-borne encephalitis virus structural proteins are the primary viral determinants of non-viraemic transmission between ticks whereas non-structural proteins affect cytotoxicity | |
Lattwein et al. | Pestivirus virion morphogenesis in the absence of uncleaved nonstructural protein 2-3 | |
Manickam et al. | Modeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infections | |
Bittar et al. | Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response | |
Sarwar et al. | NS4A protein as a marker of HCV history suggests that different HCV genotypes originally evolved from genotype 1b | |
McElroy et al. | Characterization of an infectious clone of the wild-type yellow fever virus Asibi strain that is able to infect and disseminate in mosquitoes | |
WO2008136470A1 (ja) | Hcv遺伝子 | |
WO2005032329A3 (en) | Methods and compositions for identifying anti-hcv agents | |
Pham et al. | Efficient hepatitis C virus genotype 1b core-NS5A recombinants permit efficacy testing of protease and NS5A inhibitors | |
Suzuki et al. | Positively selected amino acid sites in the entire coding region of hepatitis C virus subtype 1b | |
WO2016066171A1 (en) | Optimized hcv full-length infectious cell culture systems and applications thereof |